Bryan Wasson, DO
Internal Medicine · Flower Mound, TXNPI 1972537801
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,140 of the $136,196 with a category attached, or 75.7%. Amgen accounts for 73.5% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2023 at $40,278 and has fallen 71.9% since, to $11,300 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,113 payments — averaging $122.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$100K
- Amarin Pharma, Inc.$12K
- Esperion Therapeutics, Inc.$7K
- AstraZeneca$2K
- Boehringer Ingelheim$2K
- AbbVie$2K
- plus $11K from 54 others
What the payments were for
- Consulting fees$6400%
- Speaking & faculty fees$103,14076%
- Travel & lodging$9,1767%
- Food & beverage$23,18917%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$136,196 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 117 | $157,471 |
| MounjaroTirzepatide | 87 | $121,521 |
| OzempicSemaglutide | 59 | $66,466 |
| Dupixent PenDupilumab | 14 | $59,811 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $24,789 |
| Repatha SureclickEvolocumab | 32 | $22,428 |
| VascepaIcosapent Ethyl | 21 | $20,441 |
| EliquisApixaban | 13 | $19,137 |
| FarxigaDapagliflozin Propanediol | 11 | $16,327 |
| Repatha SyringeEvolocumab | 23 | $13,401 |
| LinzessLinaclotide | 18 | $12,135 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,542 |
| FiaspInsulin Aspart (Niacinamide) | 12 | $9,762 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $8,650 |
| Icosapent Ethyl | 19 | $6,985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $1,983 | $157,471117 claims |
| Lilly USA, LLCMounjaro | $1,272 | $121,52187 claims |
| Novo NordiskOzempic, Fiasp | $1,660 | $76,22871 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $778 | $20,19231 claims |
| PfizerEliquis | $1,035 | $19,13713 claims |
| AstraZenecaFarxiga | $2,030 | $16,32711 claims |
| AbbVieLinzess, Synthroid, Armour Thyroid | $1,763 | $15,17664 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Flower Mound
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.